MedTrace Logo

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

NCT01891344 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 491

Last updated 2023-06-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

Conditions

Interventions

DRUG

Oral rucaparib

600 mg BID

Sponsors & Collaborators

  • Foundation Medicine

    collaborator INDUSTRY

  • Myriad Genetics, Inc.

    collaborator INDUSTRY

  • pharmaand GmbH

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-30
Primary Completion
2019-11-05
Completion
2021-09-28

Countries

  • United States
  • Australia
  • Canada
  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01891344 on ClinicalTrials.gov